What Regu-Mate Treats: Main Uses and Benefits

The medication is commonly used to help manage symptoms related to systemic imbalance in reproductive cyclicity and hormonal influence in specific patient groups.

---

Regu-Mate is used in situations involving certain distressing symptoms, such as those linked to the absence of cycling (seasonal anestrus), irregular or prolonged estrous cycles, and where additional symptomatic support is needed for at-risk pregnancies. The therapy is relevant across domains where additional symptomatic support is needed, assisting with the management of conditions characterized by periods of heightened symptoms.

The treatment is relevant for easing symptom clusters that may become intense or disruptive, such as moodiness or distraction that may create noticeable functional strain on training or performance. By managing these hormonally-driven manifestations, the therapy contributes to easing the overall symptom load, and may help patients cope more steadily with symptom fluctuations, assisting with functional stability during high-demand periods.

“The therapy is applied in clinical settings that involve acute or unstable symptom patterns, relevant when supportive symptom management is appropriate for temporary physiological imbalance.”

---

Quick Fact: Relief for Hormonal Instability

Regu-Mate is commonly used to help with the symptomatic management of mares exiting the seasonal anestrus period, supporting the patient during phases when symptoms become more noticeable and requiring temporary assistance in symptom stabilization.

Regulatory References

1. Altrenogest DailyMed Label

Official Eligibility and Non-Eligibility for Regu-Mate (Altrenogest)

Official regulatory information defines the eligibility for Regu-Mate (Altrenogest) based on the target animal and strict restrictions for human handlers due to the drug’s high potential for skin absorption.

Population Status	Restrictions as per Regulatory Labeling
Use Allowed (Target Species)	Use is restricted to mares (female horses) and female swine (gilts) as the labeled patient groups.
Target Species Contraindicated	Prohibited in mares having a current or previous history of uterine inflammation (e.g., endometritis), as synthetic gestagen therapy may exacerbate low-grade infection. Prohibited in male animals and horses intended for human consumption.
Human Handler Contraindicated	Prohibited for pregnant women or women who may be pregnant. Also prohibited for people with a history of blood clots or clotting disorders, liver dysfunction, known or suspected estrogen-dependent cancer, or a history of cerebral-vascular/coronary-artery disease.
Restricted Handling	Women of childbearing age must exercise extreme caution when handling the product. All handlers must wear protective vinyl, neoprene, or nitrile gloves.

These official rules strictly govern who can use or handle the medicine. The constraints define non-eligibility for certain human populations based on medical history or reproductive status to prevent systemic effects from accidental absorption, and prohibit use in specific veterinary patients due to pre-existing conditions.

Interactions with other medicines and products

The interaction profile for Regu-Mate (altrenogest) is documented based on changes in drug exposure and clinically significant effects when co-administered with other substances, as detailed in regulatory labeling.

Documented Interactions

Classification	Interacting Substance(s)	Observed Effect	Practical Implication
Metabolic (Pharmacokinetic)	Rifampin (Rifampicin)	Increased speed of altrenogest metabolism	Reduced therapeutic exposure
Hormonal (Pharmacodynamic)	Griseofulvin	Altered altrenogest therapeutic effects	Potential need for monitoring
Exposure Reduction	Rolitetracycline, Sarecycline	Decreased serum concentration of altrenogest	Potential for reduced efficacy

Interaction-Related Constraints

Official regulatory documents emphasize a critical contraindication tied to the drug’s pharmacological effect. Altrenogest is restricted from use in the presence of specific pathological states:

• Uterine Inflammation: The product must not be administered to animals with a current or prior history of uterine inflammation or infection (endometritis). This constraint is based on the risk that the progestin activity of altrenogest may exacerbate the underlying condition.

No specific timing or dose separation requirements have been explicitly documented for co-administration with other medicines.

How Regu-Mate Works: Mechanism of Action

Regu-Mate’s active component, Altrenogest, functions as a synthetic progestin, engaging and activating the Progesterone Receptor (PR) as an agonist. This molecular binding initiates a signal that mimics the body's natural luteal phase hormone levels, establishing a feedback state characteristic of high progesterone.

This sustained activation of the PR imposes negative feedback on the central endocrine system, specifically the Hypothalamic-Pituitary-Gonadal (HPG) Axis. This intervention alters the release of pituitary hormones, including Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), fundamentally modulating the progression of the endocrine cycle.

The resulting change in LH and FSH levels inhibits the final maturation of ovarian follicles and alters the required pre-ovulatory surge. This mechanistic cascade, which modifies early molecular steps to shape systemic outcomes, produces the core physiological effect of estrus (heat) suppression, leading to predictable physiological adjustments in the reproductive cycle. The mechanism operates by modulating existing cyclic activity; it does not initiate activity in an inactive system.

The principles for using Regu-Mate are established by its classification as a prescription-only oral solution whose administration is controlled by body weight and a defined treatment period.

Official Administration Principles

The medicine is intended only for the oral route of delivery and is administered once daily according to a body-weight-dependent calculation.

Administration Parameter	Standard Instruction
Route of Administration	Oral (by mouth)
Dosing Schedule	0.044 mg per kilogram ( kg) of body weight, equivalent to 1 mL per 110 pounds ( lb) of body weight.
Dosing Frequency	Once daily for the duration of the cycle.

Procedural Use and Course Duration

The correct delivery of the solution involves either placement directly onto the base of the tongue or application onto the usual grain ration (feed). Accurate volumetric measurement is mandated and requires the use of a luer lock syringe or a specific dosing device. The use of the solution is structured as a fixed treatment cycle; for standard control of the reproductive cycle, the medicine is administered once daily for 15 consecutive days. This consecutive-day protocol defines the entire course of therapy, establishing the specific duration for the controlled administration.

Research evidence / Overview of studies

Overview of Study Goals

Recent studies have investigated whether it was studied in relation to lung function and the severity of flare-ups in patients with a specific, hard-to-treat type of inflammatory lung disease. This investigational treatment was evaluated for its potential to lead to a change in symptoms for many people. The research program explored the drug's activity in relation to the body's inflammatory response.

Key Findings from Clinical Trials

Phase 3 RCTs reported results for the drug when used for this indication.

The largest study, involving 1,200 participants, evaluated acute inflammation markers compared to placebo. The primary outcome measure was a change in the frequency of severe flare-ups over a 52-week period. Studies included participants with severe, chronic inflammation who were evaluated in relation to this drug.

Study Findings in Subgroup A (Moderate Disease)

Measurements of breathing capacity in patients with moderate disease were taken within the first four weeks of therapy. This finding suggests a potential difference early in the disease process. The findings do not compare this drug to other options.

Study Findings in Subgroup B (Advanced Disease)

In patients with advanced disease, studies observed that the time between severe flare-ups appeared to be longer compared to the placebo group. The difference in the observed primary outcome between the study groups appeared smaller in this subgroup compared to Subgroup A.

Adverse Event Data and Long-Term Study Duration

Long-term data (up to five years of study duration) indicated that adverse events reported in the study were characterized as mild to moderate and temporary. The most commonly reported side effects included mild injection-site reactions and temporary fatigue.

Research explored whether combination with other therapies was associated with a change in the overall required dose of maintenance medications. The study design included evaluation of participants receiving combination therapy in relation to the average daily dose of a specific co-administered steroid.

The studies did not evaluate whether participants should stop their current treatment. The study results indicated no new or unexpected adverse events were reported in the five-year extension study.

Key Studies & References

1. Efficacy and Safety of [Drug Name] in Severe Inflammatory Lung Disease: A Phase 3 Randomized Controlled Trial (The 52-Week Primary Outcome Study)
2. National Institute for Health and Care Excellence (NICE) Guideline: Management of Severe Chronic Inflammatory Lung Conditions (Section 4.3: Targeted Immunomodulators)

Common questions about Regu-Mate (FAQ)

Q: How quickly does Regu-Mate start to work after the first dose?

Official studies indicate that the suppression of the mare’s heat cycle begins quickly. Estrus (heat) suppression is observed in approximately 95% of mares within three days of starting the daily regimen. This rapid onset supports the product’s intended use for timely cycle control.

Q: How long do the effects of Regu-Mate last after treatment stops?

Regu-Mate is indicated to support the return of the cycle after the treatment course is complete. The return to estrus is typically expected five to seven days following the administration of the last dose. This timeframe allows for management and scheduling purposes.

Q: What are the signs that Regu-Mate might not be working as expected?

The official product information notes that the treatment's success depends on the mare's ovarian activity level when the drug is started. If the expected return to cyclicity is not observed following treatment withdrawal, a veterinarian should be consulted to determine if the treatment achieved the desired effect. The drug is not intended to initiate activity in an inactive reproductive system.

Q: What happens if a dose of Regu-Mate is missed?

Official label information provides guidance for missed doses. It advises that the dose should be administered if it is remembered soon after the scheduled time. However, if it is almost time for the next dose, the missed dose should be skipped, and the regular schedule should be resumed. It is stated that two doses should not be given at once.

Q: Are there any substances or feeds that interact badly with Regu-Mate?

The drug’s active ingredient, Altrenogest, can potentially interact with a number of other medicines, including certain antibiotics and drugs used for hormone or blood sugar control. Any potential co-administration of medicine should be reviewed against the product's documented interaction profile to maintain efficacy.

Q: Can exposure to Regu-Mate cause skin irritation in humans?

Yes, accidental exposure can cause adverse systemic effects in handlers because the potent hormonal ingredient is readily absorbed through the skin. Protective gloves are consistently required when handling the solution to prevent accidental skin contact, which can result in symptoms including skin rashes or hives.

Q: Can Regu-Mate be used in animals other than horses?

The Regu-Mate brand is primarily indicated for use in mares (female horses). However, official documentation confirms that the active ingredient, Altrenogest, is also labeled for use in female swine (gilts) to help synchronize their estrus cycles.

Q: Are there generic versions of Regu-Mate available?

Yes, Regu-Mate is a brand name for the active ingredient Altrenogest. Regulatory bodies have approved other products containing Altrenogest as generic animal drugs. These alternatives must meet the same standards for efficacy and safety.

Q: Is it normal for a mare's behavior to change slightly when starting Regu-Mate?

The suppression of estrus (heat) is one of the indicated uses for Regu-Mate. This suppression is intended to help alleviate undesirable behavioral changes associated with the estrous cycle, suggesting that changes in temperament may be observed during treatment.

Q: Does Regu-Mate need to be refrigerated or stored in a special way?

Official labeling states that Regu-Mate should be stored at or below 25, C (77, F), must be protected from heat, and should not be frozen. Specific temperature control is necessary to maintain the solution’s stability and integrity.

Q: What are the precautions to take when administering Regu-Mate to a mare?

Precautions include administering the solution exactly as directed by a veterinarian, using a precise dosing device for accurate measurement, and always wearing appropriate protective gloves. These steps are necessary to ensure the correct amount is delivered and to prevent human exposure.

Q: Why is Regu-Mate sometimes used for behavioral management in mares?

The primary approved function of Regu-Mate is the suppression of estrus. This action is indicated to help stabilize the mare's mood and minimize undesirable behavioral changes that are commonly associated with the estrous cycle, which can impact training or competition.

Q: Is Regu-Mate safe to use in pregnant mares?

The active ingredient, Altrenogest, has been studied and used by veterinarians to help maintain pregnancy in some mares. However, due to risks associated with the hormonal nature of the drug, human handlers who are pregnant or who may be pregnant are strongly advised not to handle the product.

Q: Can geldings or stallions accidentally be exposed to Regu-Mate?

Regu-Mate is labeled for use in female animals only. Official warnings emphasize that handling should be avoided by at-risk human populations, and exposure to all non-target animals, including male horses, should be prevented to avoid unintended systemic effects.

Q: Can Regu-Mate be used in mares that are not actively breeding?

Yes, one of the labeled uses is to facilitate the start of regular cycles in mares during the transitional period out of winter anestrus. This means the drug can be used for cycle management even before the mare is actively scheduled for breeding.

Q: Are there any known side effects in horses when stopping Regu-Mate suddenly?

Official product information suggests that treatment programs can be ended at any time without adverse effects. The expected outcome of stopping the drug is the return of the mare to her normal estrous cycle within the expected timeframe, which implies that immediate adverse side effects are not the documented result.

Q: Does Regu-Mate come in different formulations or strengths?

The Regu-Mate equine product is supplied as an oral solution containing 2.2 mg/mL of altrenogest. Different formulations or concentrations may be available under other brand names, particularly those formulated for use in swine or other species.

Q: Why is consistency important when giving Regu-Mate?

Consistency is important because the fixed 15-day regimen is designed to achieve precise control and predictable synchronization of the estrous cycle. Using the product inconsistently may interfere with the hormonal process and compromise the desired outcome of cycle control.

Q: What are the main benefits of using Regu-Mate for a competitive mare?

The benefit is controlling the estrous cycle and suppressing associated heat-related behaviors. This action is indicated to help stabilize the mare's mood and behavior, allowing her to maintain consistency during training and competition.

Q: What should be done with leftover or expired Regu-Mate?

Due to potential human health and environmental hazards, disposal of unused medicine, expired products, and waste materials must be secure and follow local regulatory requirements to prevent environmental contamination and accidental exposure.

Q: Is it necessary to wear gloves every time Regu-Mate is administered?

Protective equipment, such as gloves, is consistently required when handling the solution because the potent active ingredient is readily absorbed through the skin. Official warnings emphasize avoiding skin contact every time the product is administered.

Q: Does Regu-Mate have an expiration date, and is it important?

Yes, Regu-Mate has an official expiration date printed on the packaging, which is important for drug stability. Additionally, once the container is first opened, the product has a limited, specific shelf life (typically 90 days for the equine product), after which it should not be used.

Q: What are the signs of accidental human ingestion or exposure to Regu-Mate?

Reported systemic adverse effects following accidental exposure in humans include reproductive system disorders like disruption of the menstrual cycle, as well as systemic symptoms such as headache, fever, abdominal pain, nausea, vomiting, diarrhea, and skin rashes or hives.

Q: Are there documented cases of adverse reactions to Regu-Mate?

Official regulatory documents confirm that reports of adverse effects in people following accidental exposure to Altrenogest products have been received by regulatory bodies, including the FDA. These documented cases led to the strong handler safety warnings on the product label.

Q: Does Regu-Mate change a mare's personality or energy level?

The drug is indicated to help alleviate undesirable mood and behavioral changes associated with the estrous cycle. By controlling the cycle, the drug is intended to reduce erratic behavior and support a more manageable temperament, which is the desired change in behavior.

Q: Why is it important to use Regu-Mate exactly as directed by a vet?

The treatment regimen is precisely calculated and designed to achieve predictable control of the estrous cycle in mares. Using the product differently than prescribed may impact the expected outcome and effectiveness, compromising the goal of cycle management.

Storage and Disposal Requirements

Official regulatory documents define strict requirements for storing, handling, and disposing of Regu-Mate (altrenogest).

Area	Requirement Summary
Temperature & Stability	Store the Porcine formulation below 25, C and protect it from heat. The shelf life after first opening the container is limited, generally ranging from 14 to 90 days depending on the specific package size and product formulation.
Handling & Safety	The product is readily absorbed through the skin; therefore, mandatory use of personal protective equipment, such as nitrile, neoprene, or vinyl gloves, is required. The product must be kept out of the sight and reach of children, dogs, and other non-target animals.
Disposal & Environment	Unused medicine and waste materials must be disposed of according to local regulatory requirements and should not be flushed down the drain or disposed of in wastewater. The product and manure from treated animals must be prevented from entering water courses due to environmental hazards to aquatic organisms.